Free Trial
NASDAQ:CKPT

Checkpoint Therapeutics Q1 2025 Earnings Report

Checkpoint Therapeutics logo
$4.26 0.00 (0.00%)
As of 05/30/2025

Checkpoint Therapeutics EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.10
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Checkpoint Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.53 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Checkpoint Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Checkpoint Therapeutics' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Checkpoint Therapeutics Earnings Headlines

We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
Checkpoint Therapeutics Announces Merger Progress
See More Checkpoint Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Checkpoint Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Checkpoint Therapeutics and other key companies, straight to your email.

About Checkpoint Therapeutics

Checkpoint Therapeutics (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

View Checkpoint Therapeutics Profile

More Earnings Resources from MarketBeat